Top AI Driven Radiation Therapy Solutions 2025

The global cancer burden is rapidly rising, with current approximations of lifetime cancer development risk at least in one out of five individuals. Recent data suggest that the Asian region contributes the majority of the world’s incidence of cancer, with mortality rates estimated at over 4 million in 2020 (International Agency for Research on Cancer), highlighting a burgeoning need for improved diagnostics and novel therapeutic strategies to combat this problem. Simultaneously, we are witnessing an accelerated phase in knowledge acquisition through scientific research, rapidly expanding our understanding of the molecular pathophysiology of cancers from the global ethnogeography perspective. Asian-prevalent cancers have not only been associated with genetic variants distinctive to specific countries and regions, but have also been attributed to environmental risk factors including unique dietary practices, endemic pathogen exposures, and diverse lifestyle practices. In the context of Molecular Diagnostics, this implies a molecular diversity that needs to be carefully apprised by various stakeholders in order not to miss opportunities for biomarker discovery. Broad genomic information comprising single nucleotide variations, insertions, deletions, gene fusions, microsatellite instability, and tumor mutational burden have been incorporated into the oncology clinic through commercially available assays such as FoundationOne CDx (Foundation Medicine). More recently, an Asian Pan-Cancer Assay (Tissue500, Lucence) specifically designed using Asian-centric cancer biomarkers has also been launched to serve the needs of the Asian cancer patient community, further bridging the gulf between the oncologist and the ability to implement molecularly-informed precision treatment in the clinic.